New Approaches to the Treatment of Heart Failure
暂无分享,去创建一个
[1] Patrick W Serruys,et al. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. , 2003, Journal of the American College of Cardiology.
[2] A. Bank,et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and congestive heart failure: a randomized placebo-controlled trial , 2003 .
[3] B. Lewis,et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. , 2003, Journal of the American College of Cardiology.
[4] C. O'connor,et al. Vasopressin: a new target for the treatment of heart failure. , 2003, American heart journal.
[5] M. Gheorghiade,et al. Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial , 2003, Circulation.
[6] D. Delurgio,et al. Effect of Cardiac Resynchronization Therapy on Left Ventricular Size and Function in Chronic Heart Failure , 2003, Circulation.
[7] P. Ponikowski,et al. Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging , 2003, Circulation.
[8] A. Hagège,et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. , 2003, Journal of the American College of Cardiology.
[9] T Douglas Bradley,et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. , 2003, The New England journal of medicine.
[10] V. Somers,et al. Central Sleep Apnea in Left Ventricular Dysfunction: Prevalence and Implications for Arrhythmic Risk , 2003, Circulation.
[11] M. Zile,et al. Selective Matrix Metalloproteinase Inhibition With Developing Heart Failure: Effects on Left Ventricular Function and Structure , 2003, Circulation research.
[12] C. Lang,et al. Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure , 2003, Circulation.
[13] Paul W Armstrong,et al. Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes: Insights From a Cohort of 12 065 Patients With New-Onset Heart Failure , 2003, Circulation.
[14] W. Colucci,et al. Sustained Hemodynamic Effects of Intravenous Levosimendan , 2003, Circulation.
[15] A. Takeshita,et al. Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction , 2002, Circulation.
[16] E. Bocchi,et al. Sildenafil Effects on Exercise, Neurohormonal Activation, and Erectile Dysfunction in Congestive Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Study Followed by a Prospective Treatment for Erectile Dysfunction , 2002, Circulation.
[17] J. Cleland,et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.
[18] A. Struthers,et al. Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure , 2002, Circulation.
[19] D. Delurgio,et al. Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.
[20] G. Fonarow,et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. , 2002, Journal of the American College of Cardiology.
[21] S. Archer,et al. Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension Comparison With Inhaled Nitric Oxide , 2002 .
[22] J. Ghali,et al. Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure , 2001 .
[23] D. Kass,et al. Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy , 2001, Circulation.
[24] Thomas Lavergne,et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay , 2001 .
[25] F. Spinale,et al. Matrix Metalloproteinase Inhibition Attenuates Left Ventricular Remodeling and Dysfunction in a Rat Model of Progressive Heart Failure , 2001, Circulation.
[26] F. Ruschitzka,et al. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? , 2001, Journal of the American College of Cardiology.
[27] D. Sawyer,et al. Cell Therapy Attenuates Deleterious Ventricular Remodeling and Improves Cardiac Performance After Myocardial Infarction , 2001, Circulation.
[28] J. Daubert,et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. , 2001, The New England journal of medicine.
[29] B. Bozkurt,et al. Results of Targeted Anti–Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure , 2001, Circulation.
[30] K. Sliwa,et al. Beneficial Effects of Pentoxifylline in Patients With Idiopathic Dilated Cardiomyopathy Treated With Angiotensin-Converting Enzyme Inhibitors and Carvedilol: Results of a Randomized Study , 2001, Circulation.
[31] W. Abraham,et al. Rationale and design of a randomized clinical trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with advanced heart failure: the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). , 2000, Journal of cardiac failure.
[32] T. Lüscher,et al. Endothelins and Endothelin Receptor Antagonists: Therapeutic Considerations for a Novel Class of Cardiovascular Drugs , 2000, Circulation.
[33] S. Gottlieb,et al. Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure , 2000, Circulation.
[34] V. Dilsizian,et al. Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease , 2000, Circulation.
[35] W. Colucci,et al. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. , 2000, Circulation.
[36] M. Pfeffer,et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial , 2000, The Lancet.
[37] A. H. Garlick,et al. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. , 2000, Journal of the American College of Cardiology.
[38] P. Rahko,et al. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. , 2000, Journal of the American College of Cardiology.
[39] D. Singer,et al. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. , 2000, Circulation.
[40] A. Logan,et al. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. , 2000, Circulation.
[41] S. Gottlieb,et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. , 2000, Circulation.
[42] R. Hajjar,et al. Prospects for gene therapy for heart failure. , 2000, Circulation research.
[43] J. Guerrero,et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[44] W. Abraham,et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. , 1999, Journal of the American Society of Nephrology : JASN.
[45] W. Abraham,et al. Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.
[46] B. Bozkurt,et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. , 1999, Circulation.
[47] A. H. Drummond,et al. Preclinical and Clinical Studies of MMP Inhibitors in Cancer , 1999, Annals of the New York Academy of Sciences.
[48] C. H. Chen,et al. Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. , 1999, Circulation.
[49] P. Hunziker,et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. , 1998, Circulation.
[50] G. Maurer,et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. , 1998, Journal of the American College of Cardiology.
[51] Y. Sun,et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. , 1998, Circulation.
[52] D. Mann,et al. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. , 1998, Circulation.
[53] S. Javaheri,et al. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. , 1998, Circulation.
[54] W. Abraham,et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. , 1998, Journal of the American College of Cardiology.
[55] D. Chatel,et al. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. , 1998, Circulation.
[56] D. Fukai,et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. , 1998, Journal of the American College of Cardiology.
[57] Y. Sugishita,et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure , 1996, Nature.
[58] P. Singal,et al. Role of oxidative stress in transition of hypertrophy to heart failure. , 1996, Journal of the American College of Cardiology.
[59] H. Oral,et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.
[60] J. Levijoki,et al. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. , 1995, Journal of molecular and cellular cardiology.
[61] P. Hunziker,et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure , 1995, The Lancet.
[62] S. Yusuf,et al. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction , 1995 .
[63] J. Levijoki,et al. Troponin C–Mediated Calcium Sensitization Induced by Levosimendan Does Not Impair Relaxation , 1995, Journal of cardiovascular pharmacology.
[64] M. Kinoshita,et al. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. , 1994, Journal of the American College of Cardiology.
[65] J. Morrow,et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[66] H. Herrmann,et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. , 1990, Circulation.
[67] R. Cody,et al. Plasma and Platelet Vasopressin in Essential Hypertension and Congestive Heart Failure , 1983, Hypertension.